Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 36,665	$ 56,464
Marketable investments	90,217	0
Accounts receivables, net	18,715	15,506
Inventory	8,106	1,831
Prepaid expenses	11,804	8,712
Other current assets	7,482	3,721
Total current assets	172,989	86,234
Property and equipment, net	41,325	31,861
Operating lease right-of-use assets	85,173	42,052
Intangibles, net	259,705	73,675
Goodwill	79,525	43,554
Equity investments	51,271	256,397
Other assets, net	4,830	2,049
Total assets	694,818	535,822
Current liabilities:
Accounts payable	27,414	24,706
Accrued payroll and related benefits	21,503	20,859
Accrued expenses	37,975	19,198
Current portion of deferred revenue	1,108	4,485
Current portion of operating lease liabilities	11,539	3,626
Current portion of contingent consideration	7,934	398
Current portion of debt	31,980	23,208
Total current liabilities	139,453	96,480
Long-term debt, net of discount	110,627	92,258
Deferred tax liabilities, net	2,426	6,918
Deferred revenue	118,942	113,185
Derivative liabilities	35,700	35,400
Operating lease liabilities	83,431	50,301
Contingent consideration	124,349	549
Other long-term liabilities	1,761	0
Total liabilities	616,689	395,091
Commitments and contingencies (Note 11)
Sorrento Therapeutics, Inc. equity
Common stock, $0.0001 par value; 750,000,000 shares authorized and 314,573,225 and 275,285,582 shares issued and outstanding at December 31, 2021 and 2020, respectively	32	28
Additional paid-in capital	1,513,758	1,172,346
Accumulated other comprehensive income	1,026	520
Accumulated deficit	(1,386,604)	(958,279)
Treasury stock, 7,568,182 shares at cost at December 31, 2021 and 2020	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders' equity	78,748	165,151
Noncontrolling interests	(619)	(24,420)
Total equity	78,129	140,731
Total liabilities and equity	$ 694,818	$ 535,822